Catherine Moukheibir has joined the board of gene and cell therapy group Oxford Biomedica as an independent non-executive director.
Moukheibir has extensive international experience in finance, capital markets and life sciences. She is a former CFO of Movetis, where she oversaw the company’s IPO on Euronext and its subsequent sale to Shire Pharmaceuticals. She currently serves as a non-executive board member at companies including Biotalys, Ironwood Pharmaceuticals, Asceneuron, DNA Script and Noema Pharma.
Dr Roch Doliveux, chair of Oxford Biomedica, said: “I am delighted to welcome Catherine to the board. Her international and impressive diverse experience as CEO, CFO and board member of a broad range of healthcare companies and financial institutions will be very valuable as we continue to strengthen our position as a life-saving cell and gene therapy company.”